Piper Sandler Reiterates a Buy on PROCEPT BioRobotics Corporation (PRCT)

Core Viewpoint - PROCEPT BioRobotics Corporation is recognized as a fast-growing small-cap stock, with analysts maintaining a Buy rating despite a price target reduction from $55 to $50 following strong fiscal Q3 2025 results [1][2]. Financial Performance - The company reported a revenue increase of 42.76% to $83.33 million, exceeding estimates by $2.56 million [2]. - The earnings per share (EPS) of negative $0.38 also surpassed consensus expectations by $0.04 [2]. Product and Market Demand - Revenue growth is attributed to strong demand for the HYDROS Robotic System, which saw a year-over-year growth of 43%, alongside increasing adoption of Aquablation therapy [2][3]. - PROCEPT BioRobotics develops the AQUABEAM Robotic System, a surgical robot that utilizes real-time imaging and a heat-free water jet for precise prostate tissue removal [4]. Analyst Insights - Analyst Matthew O'Brien noted that the company's Q3 performance was better than expected, with sales forecasts for 2025 and 2026 aligning closely with Wall Street's expectations [3]. - Concerns regarding soft utilization performance and investor destocking are viewed as temporary issues, attributed to internal changes within the company [3].